anti-tumor effectiveness
![ASCO 2023: Patients with HER2-positive mCRC experience anti-tumor effectiveness when administered a reduced dosage of Trastuzumab Deruxtecan.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Patients-with-HER2-positive-mCRC-experience-anti-tumor-effectiveness-when-administered-a-reduced-dosage-of-Trastuzumab-Deruxtecan.jpg)
ASCO 2023: Patients with HER2-Positive MCRC Benefit from Lower Dose of Trastuzumab Deruxtecan
SG Tylor
ABSTRACT NUMBER – 3501 The Phase II DESTINY-CRC02 study, presented at the 2023 ASCO Annual Meeting, reported that administering ENHERTU ...